Can Texas Instruments’ Q2 Beat and Softer Outlook Reframe Its AI-Fab Investment Story for TXN?

Texas Instruments Incorporated

Texas Instruments Incorporated

TXN

0.00

  • Texas Instruments recently reported past second-quarter 2026 results, with sales rising to US$5.46 billion and net income reaching US$1.98 billion, and issued third-quarter guidance for revenue of US$5.65 billion–US$6.15 billion and earnings per share of US$2.23–US$2.57.
  • Alongside this earnings update, the company’s long-running dividend growth, high payout ratio, and increasing exposure to AI-driven data center demand are drawing attention to how it balances shareholder returns with heavy fab expansion.
  • We’ll now examine how the strong Q2 results but softer Q3 outlook, especially around AI and data center demand, influence Texas Instruments’ investment narrative.

Find 55 companies with promising cash flow potential yet trading below their fair value.

Texas Instruments Investment Narrative Recap

To own Texas Instruments, you need to believe its focus on analog and embedded chips, plus heavy U.S. fab buildout, can translate strong end-market demand into durable cash generation. The latest Q2 beat highlights that story, while the softer Q3 guide and still-evolving AI data center demand put near term attention on whether new capacity will stay well used. For now, this guidance does not materially change the biggest near term catalyst or the key risk.

The most relevant recent announcement here is TI’s Q2 2026 report, where revenue rose to US$5.46 billion and net income to US$1.98 billion. That strength, alongside data center income reportedly doubling, ties directly into the main catalyst around AI driven infrastructure demand. At the same time, it sharpens the question of whether rising capex for new fabs and a high dividend payout ratio could tighten future financial flexibility if demand does not keep pace.

Yet even with solid Q2 numbers, investors should pay close attention to how high capital spending and a rich dividend commitment could strain free cash flow if...

Texas Instruments' narrative projects $26.4 billion revenue and $10.4 billion earnings by 2029.

Uncover how Texas Instruments' forecasts yield a $298.00 fair value, a 8% upside to its current price.

Exploring Other Perspectives

TXN 1-Year Stock Price Chart
TXN 1-Year Stock Price Chart

Some of the lowest ranked analysts painted a much more cautious picture, expecting revenue of about US$23.8 billion and earnings near US$7.6 billion by 2029, and warning that rising compliance and capacity spending could cap free cash flow even if demand, including AI data centers, stays healthy. Their view underlines how differently you can interpret the same business, and how this latest earnings and guidance update could shift those expectations in more than one direction.

Explore 5 other fair value estimates on Texas Instruments - why the stock might be worth 11% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your Texas Instruments research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
  • Our free Texas Instruments research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Texas Instruments' overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

  • Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
  • The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
  • AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.